1. Home
  2. KEY vs ILMN Comparison

KEY vs ILMN Comparison

Compare KEY & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KeyCorp

KEY

KeyCorp

HOLD

Current Price

$20.49

Market Cap

22.6B

Sector

Finance

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$134.65

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEY
ILMN
Founded
1825
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.6B
18.9B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
KEY
ILMN
Price
$20.49
$134.65
Analyst Decision
Buy
Hold
Analyst Count
14
15
Target Price
$20.25
$114.93
AVG Volume (30 Days)
17.9M
1.6M
Earning Date
01-20-2026
10-30-2025
Dividend Yield
3.97%
N/A
EPS Growth
34785.88
N/A
EPS
0.86
4.46
Revenue
$5,934,000,000.00
$4,288,000,000.00
Revenue This Year
$77.19
N/A
Revenue Next Year
$6.55
$2.08
P/E Ratio
$23.89
$30.24
Revenue Growth
22.30
N/A
52 Week Low
$12.73
$68.70
52 Week High
$20.84
$153.06

Technical Indicators

Market Signals
Indicator
KEY
ILMN
Relative Strength Index (RSI) 75.76 68.81
Support Level $18.26 $126.44
Resistance Level $19.73 $137.09
Average True Range (ATR) 0.43 3.52
MACD 0.23 0.01
Stochastic Oscillator 87.37 81.58

Price Performance

Historical Comparison
KEY
ILMN

About KEY KeyCorp

With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: